Decision-Grade Alzheimer’s Biology: Enhancing Translational Confidence with Biomarker-Driven Alzheimer’s iPSC Panels
2:00 pm - Wednesday 4th February 2026
- Building Decision-Grade Preclinical Models: Leverage diverse patient-derived iPSC panels to capture Alzheimer’s heterogeneity
- Precise, biomarker-driven patient response stratification: Enables robust identification of biomarkers and supports patient stratification into responder, moderate, and non-responder groups
- De-risk pipeline decisions with human iPSC-powered predictive modeling: Embed patient-relevant biology and high-resolution biomarker analytics into preclinical workflows to confidently prioritize assets with the highest translational potential
